Pfizer's weight loss pivot: a £7.3 billion ai opportunity for savvy investors
Pfizer is back in the weight loss drug race, acquiring Medcurrent for up to £7.3 billion. This isn't just big pharma news; it's a monumental AI oppor...
Pfizer is back in the weight loss drug race, acquiring Medcurrent for up to £7.3 billion. This isn't just big pharma news; it's a monumental AI oppor...
Forget speculation! This is how you, an astute investor, can leverage AI to uncover the next groundbreaking biotech before anyone else, taking cues fr...
Explosive news! The US just sealed a flurry of new trade deals, especially with South Korea's eye-watering $350 billion investment into critical secto...
This is a brutal but essential war story. An analyst slapped a $0 price target on drugmaker Sarepta after a third death was linked to its gene thera...